Kovid-19 - Huvemek® Phase 2 clinical trial

Huvemek, Press Release, EudraCT2020-002091-12, Mar 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19ivm.org/petkov.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,600+ studies for 131 treatments. c19ivm.org

Multicenter double-blind RCT with 100 hospitalized patients in Bulgaria showing faster viral clearance, greater clinical improvement, and improved biomarkers with treatment. Limited data has been reported currently. No serious adverse events were observed.

Authors administered ivermectin on an empty stomach. Ivermectin is a lipophilic drug with low aqueous solubility and is better absorbed when given with food, especially high-fat meals. Administration with a high-fat meal can significantly increase plasma and tissue concentrations (~2.5x plasma concentration in Guzzo) and reduce time to onset of action. Standard practice for systemic use of ivermectin is administration with food (for intestinal parasitic infections, systemic distribution may not be required). Specifying fasted administration may avoid or delay the attainment of therapeutic concentrations and raises concerns about possible investigator bias.

This is the 21st of 52 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000021.

This is the 44th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

Important missing comments or errors? Let us know.

risk of no improvement, 31.6% lower, RR 0.68, p = 0.28, treatment 13 of 50 (26.0%), control 19 of 50 (38.0%), NNT 8.3, patients with improvement on WHO scale, day 7.

risk of no improvement, 31.8% lower, RR 0.68, p = 0.21, treatment 15 of 50 (30.0%), control 22 of 50 (44.0%), NNT 7.1, patients with improvement on WHO scale, day 6.

risk of no improvement, 36.0% lower, RR 0.64, p = 0.10, treatment 16 of 50 (32.0%), control 25 of 50 (50.0%), NNT 5.6, patients with improvement on WHO scale, day 5.

risk of no improvement, 34.5% lower, RR 0.66, p = 0.07, treatment 19 of 50 (38.0%), control 29 of 50 (58.0%), NNT 5.0, patients with improvement on WHO scale, day 4.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Guzzo et al., Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, J. Clinical Pharmacology, doi:10.1177/009127002237994.wiley.com, doi.org.

Huvemek et al., 25 Mar 2021, Double Blind Randomized Controlled Trial, Bulgaria, preprint, 1 author, average treatment delay 7.0 days, dosage 400μg/kg days 1-3, trial EudraCT2020-002091-12.

This Paper Ivermectin All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0